Sunflower Pharmaceutical GroupLtd's high ROE is impressive, likely driving its significant earnings growth. Despite retaining a small portion of profits, it has managed to increase earnings, a positive sign. The company's performance is quite pleasing overall.
Market expectations for growth seem moderated, with average annual share price increase of 26% lower than EPS growth. Positive sentiment around the company may hint at business momentum.
葵花藥業股票討論區
暫無評論